Fluoroquinolones (FQ) of the ofloxacin/ciprofloxacin generation were mainly active against Gram-negative bacteria, distinguishing themselves as cidal IV/PO drugs with high potency against most lactose- and non-lactose fermenters. They were excellent against problem pathogens like P. aeruginosa, had excellent efficacy against Salmonellae, the Gonococcus
Continue reading MRSA Fluoroquinolones – An Interesting Bunch Playing a High-Stakes Game → Like this: Like Loading...
Posted in The News, The Viewpoint |
Tagged Acorafloxacin, Actavis, Allergen, antibiotic blog, AstraZeneca, Avarofloxacin, Avelox, AZD-0914, Bayer, Cipro, ciprofloxacin, delafloxacin, Dong Wha, DW-224a, Entasis, finafloxacin, Forest, Furiex, gatifloxacin, JNJ, levofloxacin, Levoquin, linezolid, Melinta, MerLion, moxifloxacin, MPC, MRSA, mutation frequency, mutation prevention concentration, Nemonoxacin, Rib-X, TaiGen, Tequin, TG-873870, WCK-2349, WCK-771, Wockhardt, zabofloxacin, Zyvox |
>>> For the latest QIDP list, please click HERE <<< Since our last QIDP blog from April 8, 2015, several new drugs have made the list which now includes 41 compounds. Below a table which includes compound, sponsor and development stage (Phase). It
Continue reading QIDP Drugs – 4th Edition → Like this: Like Loading...
Posted in Recent Literature, The News |
Tagged Achaogen, Acorafloxacin, Actavis, Actavis/Furiex, Actelion Pharmaceuticals, AFN-1252, Amikacin + fosfomycin, antibiotic blog, AR-100, Aradigm Pharmaceuticals, ARD-3100/3150/1100, Arikace, Astellas, AstraZeneca / Entasis, Avarofloxacin, AZD-0914, BAL-30072, Basilea, BC-3781, BisEDT Antimicrobial Gel, Brilacidin, Cadazolid, carbavance, Cardeas Pharma, CB-315, CD-101, Ceftazidime + avibactam, Ceftolozane + tazobactam, Cellceutix Pharmaceuticals, CEM-101, CEM-102, Cempra Pharmaceuticals, Cidara Therapeutics, ciprofloxacin, Cubist, dalbavancin, Deb-1450, Deb-1452, Debiopharm Pharmaceuticals, delafloxacin, Durata Therapeutics, eravacycline, ETX-0914, FDA, finafloxacin, Fusidic Acid, iclaprim, Imipenem/cilastatin + MK-7655, Insmed Pharmaceuticals, isavuconazole, JNJ-Q2, lefamulin, ME-1100, Meiji Seika Pharma, Melinta Therapeutics, Merck, MerLion Pharmaceuticals, Meropenem + RPX7009, Microbion Corporation, minocycline, MK-4261, Motif, Nabriva Therapeutics, Nemonoxacin, nikkomycin, NikZ, omadacycline, OP-1068, oritavancin, Paratek Pharmaceuticals, plazomicin, PMX-30063, POL-7080, PTK-0796, QIDP drugs, QIDP list, QIDP list of antibiotics, Radezolid, RedHill Biopharma, relebactam, RHB-105, Roche / Polyphor, RPX2014, SCY-078, Scynexis Pharmaceuticals, secnidazole, SMT-19969, solithromycin, Summit plc, Surotomycin, SYM-1219, Symbiomix, TaiGen Biotechnology, Taigexyn, tedizolid, Tetraphase Pharmaceuticals, TG-873870, The Medicines Company, Torezolid, Trius, Valley Fever Solutions, WCK-2349, WCK-4873, WCK-771, Wockhardt, Wockhardt Pharmaceuticals |
For the latest QIDP listing, please click HERE Since FDA issued the QIDP designation in 2012, many companies have requested this important ‘label’. Which should not come as a surprise: QIDP status confers significant benefits – and there is no
Continue reading Antibiotics with QIDP Designation – – – Updated 9-30-14 → Like this: Like Loading...
Posted in QIDP Antibiotics, The News |
Tagged antibiotic class, carbavance, Ceftazidime/avibactam, ceftolozane, ceftolozane/tazobactam, dalbavancin, Dalvance, delafloxacin, development, enfumafungin, eravacycline, FabI, FDA, finafloxacin, isovuconazole, mode of action, NVX-104, omadacycline, Orbactiv, oritavancin, plazomicin, relebactam, SCY-078, Sivextro, solithromycin, tedizolid |